類澱粉沉積症藥物市場規模、佔有率和成長分析（按治療方法、給藥途徑、適應症、最終用戶、通路和地區分類）—2026-2033年產業預測

預計到 2024 年，全球類澱粉沉積症治療市場規模將達到 228.5 億美元，到 2025 年將達到 259.8 億美元，到 2033 年將達到 725.8 億美元，預測期（2026-2033 年）的複合年成長率為 13.7%。

全球類澱粉沉積症變性治療市場正經歷顯著成長，其主要促進因素包括盛行率上升、公眾認知度提高以及臨床和診斷能力的進步。新型標靶治療方法的出現顯著提升了安寧療護的需求，而人口老化加劇了類澱粉沉積症風險，進一步推動了市場擴張。政府的支持性政策，例如孤兒藥激勵措施，透過經濟補貼和加速核准流程，促進了治療方法的推廣應用。此外，醫護人員和病患意識提升也有助於早期發現和採用治療方案。人工智慧和機器學習等先進技術的融合，正在推動藥物研發和個人化醫療的發展；物聯網和擴增實境正在改善病患監測和介入策略，最終將改變類澱粉沉積症變性治療的格局。

推動全球類澱粉沉積症藥物市場發展的因素

人們對類澱粉沉積症的認知不斷提高，診斷能力的提升也推動了該領域治療藥物的需求成長。隨著越來越多先前被忽視的罕見疾病病例被確診，對有效治療方案的需求日益凸顯。此外，先進的治療調查方法正在促進市場擴張，而醫療報銷政策的改善也提高了患者獲得診斷和治療服務的便利性。這些因素共同推動了類澱粉沉積症治療藥物市場的發展，患者和醫療服務提供者都在尋求應對這一複雜健康問題的有效解決方案。

限制全球類澱粉沉積症藥物市場的因素

全球類澱粉沉積症變性治療市場面臨許多重大挑戰，阻礙了患者接受治療和產業投資。複雜的藥物、特殊的治療通訊協定以及長期照護帶來的高昂費用，可能會使患者望而卻步。此外，新藥研發（包括RNA治療方法）帶來的巨額資金負擔，也可能抑制製藥公司在該領域進行創新投入。另外，類澱粉沉積症變性的罕見性和危及生命的性質，以及其潛在的致命後果，進一步阻礙了患者積極尋求和接受現有治療方案。

類澱粉沉積症治療市場的全球趨勢

全球類澱粉沉積症變性治療市場正見證著RNA療法應用顯著成長，主要得益於其高效率性和成本效益。患者越來越傾向於選擇這類治療方法，因為它們能夠直接針對疾病的根本原因，並以極低的劑量提供長期療效。此外，研發活動的激增以及生技和製藥公司採取的創新策略，也進一步增強了患者對RNA療法的信心。這種模式轉移預示著類澱粉沉積症治療的未來充滿希望，並有望推動相關技術的進步，從而改善患者預後並重塑治療格局。

目錄

介紹

• 調查目標
• 調查範圍
• 定義

調查方法

• 資訊收集
• 二手資料和一手資料方法
• 市場規模預測
• 市場假設與限制

執行摘要

• 全球市場展望
• 供需趨勢分析
• 細分市場機會分析

市場動態與展望

• 市場規模
• 市場動態
  • 促進因素和機遇
  • 限制與挑戰
• 波特分析

關鍵市場考察

• 關鍵成功因素
• 競爭程度
• 關鍵投資機會
• 市場生態系統
• 市場吸引力指數（2025）
• PESTEL 分析
• 總體經濟指標
• 價值鏈分析
• 定價分析
• 技術評估
• 監管環境
• 客戶和購買標準分析
• 管道分析
• 疾病流行病學

全球類澱粉沉積症藥物市場規模（依治療方法分類）及複合年成長率（2026-2033 年）

• 化療
• 幹細胞移植
• 標靶治療
• 支持性治療和手術
• 其他

全球類澱粉沉積症藥物市場規模（按給藥途徑和複合年成長率分類）（2026-2033 年）

• 口服
• 靜脈注射
• 皮下注射

全球類澱粉沉積症藥物市場規模（按應用及複合年成長率分類）（2026-2033 年）

• AL類澱粉沉積症
• ATTR類澱粉沉積症
• AA型類澱粉沉積症
• 野生型 ATTR

全球類澱粉沉積症藥物市場規模（按最終用戶分類）及複合年成長率（2026-2033 年）

• 醫院和診所
• 門診手術中心
• 居家醫療環境
• 其他

全球類澱粉沉積症藥物市場規模（按分銷管道分類）及複合年成長率（2026-2033 年）

• 醫院藥房
• 零售藥房
• 線上

全球類澱粉沉積症藥物市場規模及複合年成長率（2026-2033）

• 北美洲
  • 美國
  • 加拿大
• 歐洲
  • 德國
  • 西班牙
  • 法國
  • 英國
  • 義大利
  • 其他歐洲地區
• 亞太地區
  • 中國
  • 印度
  • 日本
  • 韓國
  • 亞太其他地區
• 拉丁美洲
  • 巴西
  • 其他拉丁美洲地區
• 中東和非洲
  • 海灣合作理事會國家
  • 南非
  • 其他中東和非洲地區

競爭資訊

• 前五大公司對比
• 主要企業的市場定位（2025 年）
• 主要市場參與者所採取的策略
• 近期市場趨勢
• 公司市佔率分析（2025 年）
• 主要企業公司簡介
  • 公司詳情
  • 產品系列分析
  • 依業務板塊進行公司股票分析
  • 2023-2025年營收年比比較

主要企業簡介

• Pfizer Inc.（USA）
• Alnylam Pharmaceuticals（USA）
• Ionis Pharmaceuticals（USA）
• AstraZeneca（UK）
• Johnson & Johnson（USA）
• Novo Nordisk A/S（Denmark）
• BridgeBio Pharma（USA）
• Prothena Corporation（Ireland）
• Alexion Pharmaceuticals（USA）
• Takeda Pharmaceutical Company（Japan）
• Attralus（USA）
• Caelum Biosciences（USA）
• Zentalis Pharmaceuticals（USA）
• GlaxoSmithKline plc（GSK）（UK）
• Intellia Therapeutics（USA）
• Sanofi（France）
• F. Hoffmann-La Roche（Switzerland）
• Akcea Therapeutics（USA）
• Bristol-Myers Squibb Company（USA）
• Regeneron Pharmaceuticals（USA）

結論與建議

Global Amyloidosis Therapeutics Market size was valued at USD 22.85 Billion in 2024 and is poised to grow from USD 25.98 Billion in 2025 to USD 72.58 Billion by 2033, growing at a CAGR of 13.7% during the forecast period (2026-2033).

The global amyloidosis therapeutics market is experiencing significant growth driven by increasing prevalence, heightened awareness, and advancements in clinical and diagnostic capabilities. The rise of novel and targeted therapies generates substantial demand for palliative care, while an aging population predisposed to amyloidosis further propels market expansion. Supportive government policies, including orphan drug incentives, encourage the uptake of therapies through financial benefits and expedited approval processes. Moreover, heightened awareness among healthcare professionals and patients promotes early detection and adoption of treatment solutions. The integration of advanced technologies such as AI and machine learning enhances drug discovery and personalized medicine, while IoT and augmented reality improve patient monitoring and intervention strategies, ultimately transforming the landscape of amyloidosis therapeutics.

Top-down and bottom-up approaches were used to estimate and validate the size of the Global Amyloidosis Therapeutics market and to estimate the size of various other dependent submarkets. The research methodology used to estimate the market size includes the following details: The key players in the market were identified through secondary research, and their market shares in the respective regions were determined through primary and secondary research. This entire procedure includes the study of the annual and financial reports of the top market players and extensive interviews for key insights from industry leaders such as CEOs, VPs, directors, and marketing executives. All percentage shares split, and breakdowns were determined using secondary sources and verified through Primary sources. All possible parameters that affect the markets covered in this research study have been accounted for, viewed in extensive detail, verified through primary research, and analyzed to get the final quantitative and qualitative data.

Global Amyloidosis Therapeutics Market Segments Analysis

Global Amyloidosis Therapeutics Market is segmented by Therapy Type, Route of Administration, Application, End User, Distribution Channel and region. Based on Therapy Type, the market is segmented into Chemotherapy, Stem Cell Transplantation, Targeted Therapy, Supportive Care & Surgery and Others. Based on Route of Administration, the market is segmented into Oral, Intravenous and Subcutaneous. Based on Application, the market is segmented into AL Amyloidosis, ATTR Amyloidosis, AA Amyloidosis and Wild-Type ATTR. Based on End User, the market is segmented into Hospitals & Clinics, Ambulatory Surgical Centers, Home Care Settings and Others. Based on Distribution Channel, the market is segmented into Hospital Pharmacies, Retail Pharmacies and Online. Based on region, the market is segmented into North America, Europe, Asia Pacific, Latin America and Middle East & Africa.

Driver of the Global Amyloidosis Therapeutics Market

The growing awareness and improved diagnostic capabilities surrounding amyloidosis are significantly driving the demand for therapeutics in this market. As more individuals are diagnosed with this rare condition-often previously overlooked-the need for effective treatment options is becoming increasingly evident. Additionally, the shift towards advanced treatment methodologies supports market expansion, while enhanced healthcare reimbursement policies facilitate greater access to both diagnostic and therapeutic services. This combination of factors contributes to an escalating interest in the amyloidosis therapeutics market, as patients and healthcare providers seek efficient solutions for this complex health issue.

Restraints in the Global Amyloidosis Therapeutics Market

The global amyloidosis therapeutics market faces several crucial challenges that hinder patient adoption and industry investment. The high expenses associated with advanced medications, specialized treatment protocols, and prolonged care can deter individuals from pursuing necessary therapies. Furthermore, the significant financial burden linked to research and development for new drugs, including RNA-based treatments, may lead pharmaceutical companies to hesitate in committing resources to innovation in this field. Additionally, the rare and life-threatening characteristics of amyloidosis, coupled with its potential fatal outcomes, further contribute to the reluctance of patients to seek out and engage with available therapeutic options.

Market Trends of the Global Amyloidosis Therapeutics Market

The Global Amyloidosis Therapeutics market is witnessing a significant trend towards the rising adoption of RNA-based therapies, driven by their enhanced efficacy and cost-effectiveness. Patients are increasingly favoring these therapies as they directly target the underlying causes of the disease and provide long-term solutions with minimal dosing requirements. Furthermore, the surge in research and development initiatives, coupled with innovative strategies employed by biotech firms and pharmaceutical companies, is bolstering patient confidence in RNA-based treatments. This paradigm shift signifies a promising future for amyloidosis management, fostering advancements that could enhance patient outcomes and reshape therapeutic landscapes.

Table of Contents

Introduction

• Objectives of the Study
• Scope of the Report
• Definitions

Research Methodology

• Information Procurement
• Secondary & Primary Data Methods
• Market Size Estimation
• Market Assumptions & Limitations

Executive Summary

• Global Market Outlook
• Supply & Demand Trend Analysis
• Segmental Opportunity Analysis

Market Dynamics & Outlook

• Market Overview
• Market Size
• Market Dynamics
  • Drivers & Opportunities
  • Restraints & Challenges
• Porters Analysis
  • Competitive rivalry
  • Threat of substitute
  • Bargaining power of buyers
  • Threat of new entrants
  • Bargaining power of suppliers

Key Market Insights

• Key Success Factors
• Degree of Competition
• Top Investment Pockets
• Market Ecosystem
• Market Attractiveness Index, 2025
• PESTEL Analysis
• Macro-Economic Indicators
• Value Chain Analysis
• Pricing Analysis
• Technology Assessment
• Regulatory Landscape
• Customer & Buying Criteria Analysis
• Pipeline Analysis
• Disease Epidemiology

Global Amyloidosis Therapeutics Market Size by Therapy Type & CAGR (2026-2033)

• Market Overview
• Chemotherapy
• Stem Cell Transplantation
• Targeted Therapy
• Supportive Care & Surgery
• Others

Global Amyloidosis Therapeutics Market Size by Route of Administration & CAGR (2026-2033)

• Market Overview
• Oral
• Intravenous
• Subcutaneous

Global Amyloidosis Therapeutics Market Size by Application & CAGR (2026-2033)

• Market Overview
• AL Amyloidosis
• ATTR Amyloidosis
• AA Amyloidosis
• Wild-Type ATTR

Global Amyloidosis Therapeutics Market Size by End User & CAGR (2026-2033)

• Market Overview
• Hospitals & Clinics
• Ambulatory Surgical Centers
• Home Care Settings
• Others

Global Amyloidosis Therapeutics Market Size by Distribution Channel & CAGR (2026-2033)

• Market Overview
• Hospital Pharmacies
• Retail Pharmacies
• Online

Global Amyloidosis Therapeutics Market Size & CAGR (2026-2033)

• North America (Therapy Type, Route of Administration, Application, End User, Distribution Channel)
  • US
  • Canada
• Europe (Therapy Type, Route of Administration, Application, End User, Distribution Channel)
  • Germany
  • Spain
  • France
  • UK
  • Italy
  • Rest of Europe
• Asia Pacific (Therapy Type, Route of Administration, Application, End User, Distribution Channel)
  • China
  • India
  • Japan
  • South Korea
  • Rest of Asia-Pacific
• Latin America (Therapy Type, Route of Administration, Application, End User, Distribution Channel)
  • Brazil
  • Rest of Latin America
• Middle East & Africa (Therapy Type, Route of Administration, Application, End User, Distribution Channel)
  • GCC Countries
  • South Africa
  • Rest of Middle East & Africa

Competitive Intelligence

• Top 5 Player Comparison
• Market Positioning of Key Players, 2025
• Strategies Adopted by Key Market Players
• Recent Developments in the Market
• Company Market Share Analysis, 2025
• Company Profiles of All Key Players
  • Company Details
  • Product Portfolio Analysis
  • Company's Segmental Share Analysis
  • Revenue Y-O-Y Comparison (2023-2025)

Key Company Profiles

• Pfizer Inc. (USA)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Alnylam Pharmaceuticals (USA)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Ionis Pharmaceuticals (USA)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• AstraZeneca (UK)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Johnson & Johnson (USA)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Novo Nordisk A/S (Denmark)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• BridgeBio Pharma (USA)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Prothena Corporation (Ireland)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Alexion Pharmaceuticals (USA)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Takeda Pharmaceutical Company (Japan)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Attralus (USA)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Caelum Biosciences (USA)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Zentalis Pharmaceuticals (USA)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• GlaxoSmithKline plc (GSK) (UK)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Intellia Therapeutics (USA)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Sanofi (France)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• F. Hoffmann-La Roche (Switzerland)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Akcea Therapeutics (USA)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Bristol-Myers Squibb Company (USA)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Regeneron Pharmaceuticals (USA)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments

Conclusion & Recommendations